12:00 AM
Apr 13, 2009
 |  BC Week In Review  |  Company News  |  Deals

Amgen, Celldex deal

Amgen granted Celldex exclusive, worldwide rights to develop and commercialize FMS-like tyrosine kinase 3 ligand (FLT3LG) and CD40 ligand. Celldex plans to combine the molecules with others in its portfolio to create therapeutic vaccines for cancer, inflammation and infectious diseases. Possible compounds for combination include Celldex's CDX-1307 (formerly BHCG-VAC, MDX-1307), a fusion protein composed of...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >